Pfizer Oncology, a division of Pfizer for cancer, recently hosted an Innovation Day event. In their official press release, Pfizer described it as a means to reveal its integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth in the oncology sector. 

Taking place in New York on February 29, 2024, Pfizer's cancer division sought to engage with investors and the broader investment community.

This event was a big deal for the company after Pfizer bought Seagen in late 2023. This purchase, as a consequence, made Pfizer Oncology stronger and more capable in the world of cancer medicine.

READ NEXT: Drugmakers, Including Pfizer and Sanofi, Set to Raise US Prices on at Least 500 Drugs in January

How Pfizer Cancer Division Attracted Investors

During the Innovation Day event, Pfizer's investor relations saw strength. 

Executives, led by Chris Boshoff, Chief Oncology Officer and Executive Vice President, articulated the company's strategic roadmap and outlined its core objectives for the newly formed organization. 

In the event, they stated the need to bring new and better ways to treat cancer. Together with its strong lineup of medicines and its plans to keep growing, Pfizer Oncology is stepping up ahead in cancer research and treatment.

The major part of the executive presentation was Pfizers cancer division's portfolio and its research and development engine, which is poised to deliver a stream of "potential blockbuster medicines" by 2030. 

The entire pipeline boasts a diverse range of therapeutic modalities, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, reflecting Pfizer's multifaceted approach to combating cancer from various angles.

Pfizer Oncology also highlighted numerous near- and mid-term plans that are expected to drive long-term sustainable growth. These include launching new treatments, getting results from big studies, and starting new studies.

In return, Pfizer's investors were especially interested in their future endeavors. They aim to have eight or more big-selling drugs by 2030, with most of their cancer treatment revenues coming from advanced biologics, a big jump from just 6% in 2023. 

The event ended with a call for investors to join Pfizer Oncology on its journey. 

Ultimately, the goal was for the Pfizer cancer division to work with investors in their cancer research and treatments to help more people in need.

READ MORE: Pfizer Agrees to Pay $93 Million to Settle Lipitor Cholesterol Drug Antitrust Lawsuit